Alps Advisors Inc. lowered its stake in shares of United Therapeutics Co. (NASDAQ:UTHR) by 4.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 87,392 shares of the biotechnology company’s stock after selling 4,010 shares during the period. Alps Advisors Inc. owned 0.20% of United Therapeutics worth $6,970,000 at the end of the most recent reporting period.
Other large investors also recently bought and sold shares of the company. Pearl River Capital LLC purchased a new stake in shares of United Therapeutics during the second quarter worth $32,000. Private Ocean LLC purchased a new stake in shares of United Therapeutics during the second quarter worth $34,000. NEXT Financial Group Inc lifted its position in shares of United Therapeutics by 72.7% during the second quarter. NEXT Financial Group Inc now owns 475 shares of the biotechnology company’s stock worth $37,000 after acquiring an additional 200 shares in the last quarter. Quadrant Capital Group LLC lifted its position in shares of United Therapeutics by 61.2% during the third quarter. Quadrant Capital Group LLC now owns 661 shares of the biotechnology company’s stock worth $50,000 after acquiring an additional 251 shares in the last quarter. Finally, Machina Capital S.A.S. lifted its position in shares of United Therapeutics by 776.4% during the second quarter. Machina Capital S.A.S. now owns 964 shares of the biotechnology company’s stock worth $75,000 after acquiring an additional 854 shares in the last quarter. Hedge funds and other institutional investors own 94.19% of the company’s stock.
Several research analysts have recently weighed in on UTHR shares. Jefferies Financial Group raised shares of United Therapeutics from an “underperform” rating to a “hold” rating and set a $90.00 price target on the stock in a report on Thursday, August 1st. BidaskClub raised shares of United Therapeutics from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Cowen set a $118.00 price target on shares of United Therapeutics and gave the stock a “hold” rating in a report on Friday, September 13th. Wedbush reaffirmed a “buy” rating and issued a $273.00 price target on shares of United Therapeutics in a report on Thursday, August 1st. Finally, HC Wainwright reaffirmed a “hold” rating and issued a $85.00 price target on shares of United Therapeutics in a report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, five have given a hold rating, five have issued a buy rating and one has issued a strong buy rating to the stock. United Therapeutics presently has a consensus rating of “Buy” and an average price target of $120.30.
United Therapeutics stock opened at $91.61 on Friday. The stock has a market cap of $4.02 billion, a P/E ratio of 6.84 and a beta of 0.97. United Therapeutics Co. has a fifty-two week low of $74.31 and a fifty-two week high of $128.94. The firm’s fifty day moving average price is $83.92 and its 200-day moving average price is $83.94. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.91 and a current ratio of 4.11.
United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $3.16 earnings per share for the quarter, topping the consensus estimate of $2.34 by $0.82. The firm had revenue of $401.50 million for the quarter, compared to analysts’ expectations of $342.28 million. United Therapeutics had a negative net margin of 6.04% and a negative return on equity of 3.54%. The business’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $3.98 earnings per share. Sell-side analysts predict that United Therapeutics Co. will post -0.96 earnings per share for the current year.
United Therapeutics Profile
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases primarily in the United States and Europe. The company's commercial therapies include Remodulin, an infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients; and Unituxin, a monoclonal antibody for treating neuroblastoma.
See Also: How mutual funds make money
Want to see what other hedge funds are holding UTHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for United Therapeutics Co. (NASDAQ:UTHR).
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.